S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How Biden has already won 2024 (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
Top 5 AI Stocks to Buy for 2024 (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
The only accurate crypto trading system I know … (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How Biden has already won 2024 (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
Top 5 AI Stocks to Buy for 2024 (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
The only accurate crypto trading system I know … (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How Biden has already won 2024 (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
Top 5 AI Stocks to Buy for 2024 (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
The only accurate crypto trading system I know … (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How Biden has already won 2024 (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
Top 5 AI Stocks to Buy for 2024 (Ad)
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
The only accurate crypto trading system I know … (Ad)
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
Free Trial
NASDAQ:SIOX

Sio Gene Therapies (SIOX) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)
Free SIOX Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$0.45
▼
$0.48
50-Day Range
$0.38
▼
$0.48
52-Week Range
$0.25
▼
$0.50
Volume
40,400 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisSocial Media
SIOX stock logo

About Sio Gene Therapies Stock (NASDAQ:SIOX)

Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was incorporated in 2014 and is based in New York, New York.

SIOX Stock News Headlines

February 2, 2024 | finance.yahoo.com
Sio Gene Therapies, Inc. to File for Dissolution and Declare an Initial Liquidating Distribution of $0.435 Per Share
November 22, 2023 | morningstar.com
Sio Gene Therapies Inc SIOX
April 18, 2024 | Gold Safe Exchange (Ad)
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
November 1, 2023 | thestreet.com
Two Promising Gene Therapy Stocks Tackling Eye Disease
July 19, 2023 | fool.com
Sio Gene Therapies (NASDAQ: AXGT)
July 13, 2023 | finance.yahoo.com
Roivant in Talks to Sell Stomach Drug to Roche in Deal Valued at More Than $7 Billion
May 23, 2023 | nbcnews.com
A new gene therapy could be a game-changer for patients with severe anemia. The cost? $2.8 million.
February 14, 2023 | finance.yahoo.com
Sio Gene Therapies Announces Fiscal Third Quarter 2022 Financial Results
April 18, 2024 | Gold Safe Exchange (Ad)
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
January 26, 2023 | seekingalpha.com
SIOX Sio Gene Therapies Inc.
December 14, 2022 | finance.yahoo.com
Sio Gene Therapies Inc. Announces Board Approval of Plan of Complete Liquidation and Dissolution
November 10, 2022 | bizjournals.com
Following layoffs, gene therapy firm leaves Durham
November 10, 2022 | finance.yahoo.com
Sio Gene Therapies Announces Fiscal Second Quarter 2022 Financial Results
October 31, 2022 | finance.yahoo.com
Sio Gene Therapies (NASDAQ:SIOX) Will Have To Spend Its Cash Wisely
August 11, 2022 | finance.yahoo.com
Sio Gene Therapies Announces Fiscal First Quarter 2022 Financial Results
August 5, 2022 | uk.finance.yahoo.com
Sio Gene Therapies Inc. (SIOX)
June 14, 2022 | bizjournals.com
Gene therapy firm in Durham slashes headcount as biotech stumbles
June 14, 2022 | finance.yahoo.com
Sio Gene Therapies Announces Fiscal Year 2021 Year-End Financial Results
April 28, 2022 | markets.businessinsider.com
Mid-Afternoon Market Update: Nasdaq Jumps 400 Points; Sio Gene Therapies Shares Plummet
April 28, 2022 | finance.yahoo.com
Sio Gene Therapies Ditches Two Remaining Programs, Seeks Buyer(s), Shares Plunge
April 27, 2022 | finance.yahoo.com
Sio Gene Therapies Provides Corporate Update
February 11, 2022 | finance.yahoo.com
Sio Gene Therapies Announces Corporate Updates and Fiscal Third Quarter 2021 Financial Results
February 2, 2022 | benzinga.com
SVB Leerink Downgrades Sio Gene Therapies to Market Perform, Lowers Price Target to $1
February 1, 2022 | benzinga.com
HC Wainwright & Co. Maintains Buy on Sio Gene Therapies, Lowers Price Target to $7
February 1, 2022 | msn.com
The Daily Biotech Pulse: ImmunityBio Reports Positive Readout, Valneva Starts Late-Stage Chikungunya Vaccine Study, Sio Gene Shelves Parkinson's Program
January 4, 2022 | nasdaq.com
Companies Like Sio Gene Therapies (NASDAQ:SIOX) Are In A Position To Invest In Growth
November 12, 2021 | finance.yahoo.com
We're Hopeful That Sio Gene Therapies (NASDAQ:SIOX) Will Use Its Cash Wisely
See More Headlines
Receive SIOX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sio Gene Therapies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/12/2021
Today
4/18/2024
Fiscal Year End
3/31/2025
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SIOX
CUSIP
N/A
CIK
1636050
Web
siogtx.com
Phone
(646) 677-6770
Fax
N/A
Employees
12
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
No Data
Beta
1.14
Beginner's Guide to Pot Stock Investing Cover
Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. David W. Nassif J.D. (Age 70)
    CEO, CFO, Chief Accounting Officer, General Counsel & Director
    Comp: $699.52k

Key Competitors

View All Competitors

SIOX Stock Analysis - Frequently Asked Questions

How were Sio Gene Therapies' earnings last quarter?

Sio Gene Therapies Inc. (NASDAQ:SIOX) announced its earnings results on Friday, November, 12th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.17) by $0.12.

When did Sio Gene Therapies' stock split?

Shares of Sio Gene Therapies reverse split on the morning of Wednesday, May 8th 2019. The 1-8 reverse split was announced on Tuesday, May 7th 2019. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 7th 2019. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

This page (NASDAQ:SIOX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners
[Urgent!] Generational Wealth Gameplan
Crypto 101 Media
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Biden’s $374B Giveaway Into This Sector
DTI
The “Perfect Storm” for Gold
Gold Safe Exchange
Biden replacement revealed?
Paradigm Press
He Is Giving Away Bitcoin
Crypto Swap Profits
Your Money is Not Safe
American Alternative
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research